BEIJING (Reuters) – China’s Livzon Pharmaceutical Group Inc’s (Livzon) protein-based COVID-19 vaccine has obtained emergency use authorisation as a booster from the Chinese medical products regulator, the company said in a filing on Friday.
(Reporting by Beijing newsroom; editing by Jason Neely)
